Posts Tagged ‘Amgen’

AIG Takes a Beatdown

8:30pm (EST) One of my favorite trades is the “history repeats itself” trade. These are trades on stocks that you actively follow and you know how to play them on the way up AND on the way down. One such trade that has fit that bill again is American InternationalRead more

More

Market's Woes Continue

2:30pm (EST) After spending the first couple of hours in positive territory, the market has given up all of its gains as all three of the major indexes have turned negative. The S&P 500 is getting hitting the hardest as it is down nearly 1%, or 10 points, to 871.Read more

More

Amgen Looking to Open Higher

8:50am (EST) Amgen (AMGN, $52.23, up $0.18) is no stranger to the Blog and last night after the closing bell the company released some great news about one of its cancer drugs. In after-hours trading last night the stock was up $7 to $59. The company has been in lateRead more

More

Weekly Wrap for 3/22/09

1. Commentary 2. Take-Two Revisited 3. Is Dendreon Headed for Double Digits? 4. Earnings 5. Current Trades 6. Monday Morning Playbook 7. Closing Thoughts ************************************************** 1. Commentary The market got off to a good start last week but struggled to hold onto gains by the end of a five-day workRead more

More

Weekly Wrap for 3/8/09

1. Commentary 2. Bounce or No Bounce? 3. Apollo Group Heads Lower 4. Earnings 5. Current Trades 6. Monday Morning Playbook (Take-Two) 7. Closing Thoughts ************************************************** 1. Commentary The market took another pounding for the week as all three indexes lost between 6%-7%. There was a flurry of expected andRead more

More

Amgen Aching

Amgen (AMGN, $50.08, down $1.15) is no stranger to the blog and we recently closed a trade on some call options back on 2/11. I had profiled the March 60 calls (YAACL, $0.07, down $0.09) back on 2/2 and at the time they were going for $1.20. Amgen went onRead more

More

Amgen Stopped Out

Yeap, I jinxed us. In fact, I jinxed the entire market. I had mentioned Amgen’s (AMGN, $57.41, down $1.33) eight-day winning streak yesterday and that quickly came to a halt just like the rest of the market’s momentum. The March 60 calls (YAACL, $1.70, down $0.50) were recommended on FebruaryRead more

More

Weekly Wrap for 2/8/09

1. Commentary 2. Straddle’s Part 2 (Amazon Keeps on Rolling) 3. Financial Sector (open positions) 4. Akamai Technologies 5. Current Trades 6. Earnings 7. Closing Thoughts ************************************************** 1. Commentary The market had an outstanding week and it has been a minute since I have said that. For all of theRead more

More

Wednesday Morning Update

Here’s a look at what we got going on this morning… The market is in positive territory as BMad is back in the news today. You know, Bernard Madoff, the dude that milked investors for $50 billion in the world’s greatest Ponzi scheme. Bernie told the courts today that heRead more

More

Biotech Grumblings

Genentech (DNA, $82.10, up $0.86) came out with some great news yesterday after the bell and said a late-stage study combining Avastin with Tarceva to treat lung cancer was a huge success. Tarceva is a drug from OSI Pharmaceutical’s (OSIP, $36.39, up $0.79) pipeline and is marketed by Genentech. TheRead more

More

CFTC Disclosure:

GOVERNMENT REGULATIONS REQUIRE DISCLOSURE OF THE FACT THAT WHILE THESE METHODS MAY HAVE WORKED IN THE PAST, PAST PERFORMANCE IS NOT NECESSARILY INDICATIVE OF FUTURE PERFORMANCE. WHILE THERE IS A POTENTIAL FOR PROFITS THERE IS ALSO A RISK OF LOSS. A LOSS INCURRED IN CONNECTION WITH Momentum Options Trading, LLC CAN BE SIGNIFICANT. YOU SHOULD THEREFORE CAREFULLY CONSIDER WHETHER TRADING IS SUITABLE FOR YOU IN LIGHT OF YOUR FINANCIAL CIRCUMSTANCE. THERE IS SUBSTANTIAL RISK IN TRADING. A LOSS INCURRED IN CONNECTION WITH FUTURES TRADING CAN BE SIGNIFICANT. WE MAKE NO CLAIM REGARDING PAST OR FUTURE PERFORMANCE. WE MERELY TRACK EVERY TRADE AND SHOW THE PERFORMANCE OF ALL TRADES THE SYSTEM OR NEWSLETTER PRODUCES. SIMULATED TRADING IS DIFFERENT THAN TRADING REAL MONEY. HYPOTHETICAL RESULTS ARE NOT REAL RESULTS. PLEASE CONTACT YOUR BROKER ABOUT THE RISK OR TRADING STOCKS, OPTIONS OR FUTURES. ALL COMMUNICATIONS ARE OPINIONS NOT ADVICE.

CFTC RULE 4.41 – HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.